Shots:

• The companies reported that the proposed biosimilar MYL-1402O met predefined criteria for bio similarity to Avastin in a P-III trial in patients with stage IV non sq. NSCLC
• The study evaluated the efficacy, safety, and immunogenicity of MYL-1402O vs Avastin + CP CT in 671 patients with stage IV non sq. NSCLC for up to 18wks. (6 cycles), followed by monothx. with the reference drug or the biosimilar for up to 24wks.
• The study showed that the results were comparable between groups including PFS, OS, DCR & DOR; mPFS (7.6mos. vs 9.0mos); patient-reported at least 1 TEAEs (92.8% vs 92.4%)

Ref: Center for Biosimilars | Image: Viatris